Medical Implants Company for Sale in Dębica, Poland
Pre-revenue Polish MedTech manufacturer of nanotechnology-based implants and biomaterials with EU-certified facilities and rapid scalability.
| Established | 1-5 year(s) |
| Employees | 2 - 5 |
| Legal Entity | Limited Liability Company (LLC) |
| Reported Sales | Nil |
| Run Rate Sales | Nil |
| EBITDA Margin | Nil |
| Industries | Medical Implants |
| Locations | Dębica |
| Local Time | 10:46 AM Europe / Warsaw |
| Listed By | Business Owner / Director |
| Status | Moderately Active |
Full Sale
Asking Price:
USD
4.7 million
(Native Currency: EUR 4,000,000)
Reason: One of the partners is planning to exit the business and is therefore looking for full sale. We are ...
View More
Includes physical assets worth
USD
4.7 million
Name, Phone, Email
Available after connect
Business Name
Not disclosed
User Verification
Business Overview
- The company is an innovative, pre-revenue Polish MedTech enterprise operating at the intersection of nanotechnology, biomaterials, and advanced medical manufacturing.
- Owns a fully modernized 1,419 m² ISO 13485 and MDR-certified production and R&D facility on a 5,924 m² site in Dębica, Poland, completed 2 years ago, and fully compliant with EU regulatory requirements.
- Production capacity is up to 100 units of products per day.
- The business will specialize in precision dental and orthopedic implants, abutments, prosthetic components, surgical instruments, surface-modified titanium products, and regenerative biomaterials, including bioactive membranes and bone graft materials such as HA/β-TCP granules and PLA/PCL scaffolds.
- The company has actively participated in EU-funded R&D programs such as Horizon 2020, M-ERA. NET, and POIR, securing over €4 million in project grants and collaborating with more than 10 European universities and research institutes.
- Operations are lean and highly efficient, supported by a team of 4–5 skilled engineers and R&D specialists, with a rapid production cycle of 3–6 weeks from prototype to serial manufacturing.
- The company projects strong profitability with EBITDA margins of approximately 25–30%.
- Represents a ready-to-scale, EU-based manufacturing business providing international investors direct access to the European healthcare, biotechnology, and advanced materials markets without regulatory delays or startup risk.
- Owns a fully modernized 1,419 m² ISO 13485 and MDR-certified production and R&D facility on a 5,924 m² site in Dębica, Poland, completed 2 years ago, and fully compliant with EU regulatory requirements.
- Production capacity is up to 100 units of products per day.
- The business will specialize in precision dental and orthopedic implants, abutments, prosthetic components, surgical instruments, surface-modified titanium products, and regenerative biomaterials, including bioactive membranes and bone graft materials such as HA/β-TCP granules and PLA/PCL scaffolds.
- The company has actively participated in EU-funded R&D programs such as Horizon 2020, M-ERA. NET, and POIR, securing over €4 million in project grants and collaborating with more than 10 European universities and research institutes.
- Operations are lean and highly efficient, supported by a team of 4–5 skilled engineers and R&D specialists, with a rapid production cycle of 3–6 weeks from prototype to serial manufacturing.
- The company projects strong profitability with EBITDA margins of approximately 25–30%.
- Represents a ready-to-scale, EU-based manufacturing business providing international investors direct access to the European healthcare, biotechnology, and advanced materials markets without regulatory delays or startup risk.
Products & Services Overview
- Nanostructured dental and orthopedic implants, abutments, surgical instruments, and regenerative biomaterials such as nano graft HA/β-TCP composites, along with electro spun polymer membranes (PLA, PCL, chitosan, collagen).- Used for guided tissue regeneration, hemostasis, and nerve conduit applications.
- Primarily used by dental and orthopedic implant companies, hospitals, surgical centers, medical device distributors, and research institutions that source these advanced components for clinical treatments, product development, and commercialization.
Assets Overview
Tangible assets include:- Land & building (industrial land + production & R&D facility): ~€1.8 – 2.0 million.
- Plant & machinery (CNC machines, anodizing lines, laser systems, electrospinning equipment): ~€1.4 – 1.6 million.
- Laboratory & testing infrastructure (biomaterials labs, testing equipment, clean areas): ~€0.3 – 0.4 million.
- Utilities, installations & fit-outs (electricals, ventilation, safety systems, internal setup): ~€0.1 – 0.2 million.
Intangible assets include patented Plasma Electrolytic Oxidation (PEO) surface technology, laser-microstructured fibrointegrative surface intellectual property, the NanoGraft composite biomaterial platform, electrospun polymer membrane technologies (PLA, PCL, chitosan, collagen), associated know-how and process IP, medical quality certifications, rights to ongoing and completed R&D projects, the brand, website, and all licenses required for operation.
Facilities Overview
The company operates from owned industrial land and building, comprising a 1,419 m² ISO 13485 / MDR-certified production and R&D facility located on 5,924 m² of land in Dębica, Poland.
Capitalization Overview
The business is a fully registered Polish limited liability company with 100% equity ownership held by the existing shareholders and no debt or legacy liabilities. There are two shareholding partners. The company is debt-free, with ownership concentrated in the current directors.
Recent Activity
-
4 days, 1 hour agoCompany Investment, Automotive, Medical, Defense, Aerospace, Senovo, Corporate Investor / Buyer connected with the Business
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct. Note that SMERGERS is not liable for any loss, damage, costs, claims and expenses whatsoever arising from transacting with any other user from the website. The final responsibility of conducting a thorough due diligence and taking the transaction forward lies with the users. Please read best practices on SMERGERS.
Contact Business
1 Buyer contacted this Business this week.
Register below to connect now!
- Social
- Register
- Login
Who uses SMERGERS?
... and 64,500+ other businesses of all sizes.
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct.
You might also be interested in these businesses